← Leaderboards
Jonathan L Vennerstrom
University Of Nebraska Medical Center
$7,293,146
Attributed
$7,293,146
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $681.4K · FY2008–24$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,293,146 · 4
By mechanism
R01$6,201,434 · 1
R21$1,091,712 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DosePharmaceutical PreparationsParasitesLeadFeedbackDesignOralIn VivoRattusMetabolicInfectionResistance DevelopmentAdultDrug ResistanceAdolescentPraziquantelCytotoxicityCountryDrug DevelopmentDrug KineticsAffectInvestigationBaseIn Vitro
Grant awards (16)
Optimization of Antischistosomal Chemotypes$614,208
R01 · FY2024 · AI · contact PI
Optimization of Antischistosomal Chemotypes$619,621
R01 · FY2023 · AI · contact PI
Optimization of Antischistosomal Chemotypes$625,607
R01 · FY2022 · AI · contact PI
Optimization of Antischistosomal Chemotypes$642,039
R01 · FY2021 · AI · contact PI
Optimization of Antischistosomal Chemotypes$681,414
R01 · FY2020 · AI · contact PI
Optimization of Antischistosomal Chemotypes$598,659
R01 · FY2019 · AI · contact PI
Optimization of Antischistosomal Chemotypes$598,659
R01 · FY2018 · AI · contact PI
Optimization of Antischistosomal Chemotypes$598,659
R01 · FY2017 · AI · contact PI
Optimization of Antischistosomal Chemotypes$598,659
R01 · FY2016 · AI · contact PI
Optimization of Antischistosomal Chemotypes$623,909
R01 · FY2015 · AI · contact PI
Leveraging RC-12 for Radical Cure of Plasmodium Vivax$159,395
R21 · FY2014 · AI · contact PI
Leveraging RC-12 for Radical Cure of Plasmodium Vivax$212,875
R21 · FY2013 · AI · contact PI
Increasing the Antischistosomal Selectivity of Aryl Hydantoins$149,407
R21 · FY2013 · AI · contact PI
Increasing the Antischistosomal Selectivity of Aryl Hydantoins$208,193
R21 · FY2012 · AI · contact PI
Trematocidal Synthetic Perioxides$158,051
R21 · FY2009 · AI · contact PI
Trematocidal Synthetic Perioxides$203,791
R21 · FY2008 · AI · contact PI